The purpose of this study is to determine whether alteration of gut flora with rifaximin can
lead to improvement in driving performance, psychometric test performance, and quality of
life in patients with minimal hepatic encephalopathy (MHE) and cirrhosis in a randomized,
blinded, placebo-controlled trial.
Phase:
N/A
Details
Lead Sponsor:
Hunter Holmes Mcguire Veteran Affairs Medical Center
Collaborators:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.